Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph not_applicable
2
33%
Ph phase_1
1
17%
Ph phase_3
1
17%
Ph phase_2
1
17%
Ph phase_4
1
17%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 41 (16.7%)
N/A2 (33.3%)

Trials by Status

completed467%
terminated117%
unknown117%

Recent Activity

Clinical Trials (6)

Drug Details

Intervention Type
DRUG
Total Trials
6